PCM
CRL icon

Palisade Capital Management’s Charles River Laboratories CRL Stock Holding History

Palisade Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,900
Closed -$384K – 417
2019
Q3 		$384K Sell
2,900
-584
-17% -$78.3K 0.01% 373
2019
Q2 		$494K Buy
+3,484
New +$473K 0.02% 362

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Palisade Capital Management's CRL Position: Q4 2019 in Review

Palisade Capital Management sold out of Charles River Laboratories (CRL) in Q4 2019, closing a stake of 2,900 shares — an estimated $384K sold.

Palisade Capital Management first reported a position in CRL in Q2 2019 and held it in 2 quarters. The position peaked at $494K in Q2 2019. 413 funds tracked by Wall St. Rank hold CRL as of Q4 2019.

  • Palisade Capital Management reported no remaining Charles River Laboratories position as of Q4 2019 after selling out during the quarter.
  • Palisade Capital Management sold 2,900 Charles River Laboratories shares in Q4 2019, an estimated $384K.
  • Palisade Capital Management first reported a position in Charles River Laboratories in Q2 2019 and held it in 2 quarters.
  • Palisade Capital Management's Charles River Laboratories position peaked at $494K in Q2 2019.
  • 413 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2019.

Based on Palisade Capital Management's 13F filing for Q4 2019, filed 4 Feb 2020.